Ambagon Therapeutics

Ambagon Therapeutics is a biotechnology startup focused on expanding the druggable proteome by targeting intrinsically disordered proteins (IDPs), a class of proteins that have historically been considered undruggable. The company has developed a proprietary platform designed to create novel medicines capable of interacting with these challenging targets. By enabling therapeutic intervention at previously inaccessible sites within the proteome, Ambagon aims to address diseases that have eluded traditional drug discovery approaches. The company's scientific strategy centers on overcoming the limitations of conventional small molecule drugs, opening new avenues for treating complex conditions linked to IDPs.

Keywords: intrinsically disordered proteins, druggable proteome, undruggable targets, novel medicines, drug discovery, biotechnology, therapeutic platform, Ambagon Therapeutics